RESEARCH HIGHLIGHT
“The NCI EndRAD study is critically important because radiation, the current standard of care preparative regimen for children with ALL, is one of the most toxic forms of therapy. While it’s very effective at eradicating leukemia cells, it is particularly problematic in children who still have developing brains and are at high risk for neurocognitive side effects.”
Jodi L. Skiles, MD Director, Pediatric Stem Cell Transplant and Cellular Therapy, Riley Children’s Health Associate Professor of Clinical Pediatrics, IU School of Medicine > Connect with Dr. Skiles on Doximity.
LEADERS
Oncologists at Riley Children’s Health and researchers in the Brown Center for Immunotherapy at Indiana University School of Medicine are leading Phase I CAR-T cell clinical trials for acute myeloid leukemia (AML) and T-cell acute lymphocytic leukemia (ALL). Riley Children’s is also participating in a high-profile, multicenter National Cancer Institute (NCI) trial investigating the elimination of total body irradiation before stem cell transplant for certain B-ALL patients.
More about cancer research at Riley Children’s Riley Children’s provides early access to clinical trials and newly developed cancer treatments and research through the Children’s Oncology Group Phase I and Pilot Consortium. > Learn more about our program. > View active hematology and oncology clinical trials at Riley Children’s.
READ about these clinical trials making a difference for children with cancer. >
rileychildrens.org
Made with FlippingBook flipbook maker